LB 04
Alternative Names: LB-04Latest Information Update: 08 Nov 2024
Price :
$50 *
At a glance
- Originator LexBio Therapeutics
- Class Anti-inflammatories
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Research Immunological disorders; Inflammation
Most Recent Events
- 30 Aug 2024 Early research in Immunological disorders in China (unspecified route) prior to August 2024 (LexBio Therapeutics pipeline, August 2024)
- 30 Aug 2024 Early research in Inflammation in China (unspecified route) prior to August 2024 (LexBio Therapeutics pipeline, August 2024)